KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.

Rachel E Sanborn, Caicun Zhou, Ke-Jing Tang, Byoung Chul Cho, Susanna Cheng, Sanjay Popat, Akira Ono, Shun Lu, Margarita Majem, Andres Aguilar, Maria Del Rosario Garcia Campelo, Hidetoshi Hayashi, Kang-Yun Lee, Se-Hoon Lee, Angelo Delmonte, Jorge Alatorre-Alexander, Gary Richardson, Victor Santos, Christophe Dooms, Joshua K Sabari, Catherine A Shu, Nicolas Girard, Aaron S Mansfield, Keunchil Park, Yichuan Xia, Archan Bhattacharya, Nasuh Buyukkaramikli, Nolen Perualila, Joris Diels, Sandip Acharya, Conor Chandler, Irina Proskorovsky, Lindsay Dearden, Honeylet Wortman-Vayn, Parthiv J Mahadevia, Roland E Knoblauch, Trishala Agrawal, Mahadi Baig, Enriqueta Felip

Target Oncol 20(6) 979-989

PMID41184595
PMCIDPMC12669286
DOI10.1007/s11523-025-01182-0
发表日期2025-11-03
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: In the PAPILLON study, first-line amivantamab-chemotherapy in epidermal growth factor receptor (EGFR) exon 20 insertion-mutated non-small cell lung cancer demonstrated significantly prolonged progression-free survival and favorable overall survival over chemotherapy; a consistent benefit was also observed across some secondary endpoints. However, the complete clinical benefit of first-line amivantamab-chemotherapy is not fully understood, nor is the survival advantage in the presence of per-protocol crossover from chemotherapy to amivantamab after progression. OBJECTIVE: We aimed to assess time to treatment discontinuation (TTD) and time to subsequent therapy (TTST), at the time of primary analysis for progression-free survival, and the effect of the crossover design on overall survival at the time of interim analysis. METHODS: In the phase III PAPILLON study, 308 participants were randomized (amivantamab-chemotherapy, n = 153; chemotherapy, n = 155). Intravenous amivantamab was administered every 3 weeks. Chemotherapy was administered as carboplatin for four cycles and pemetrexed until disease progression. TTD and TTST were evaluated using Kaplan-Meier and Cox proportional hazards models. Crossover-adjusted survival estimates were generated using three established statistical methods. RESULTS: At a median follow-up of 14.9 months, median TTD was 13.2 versus 7.5 months for amivantamab-chemotherapy versus chemotherapy (hazard ratio [HR] 0.38 [95% confidence interval 0.28-0.51]; nominal p < 0.0001). Median TTST was 17.7 versus 9.9 months (HR 0.35 [95% confidence interval 0.25-0.49]; nominal p < 0.0001). A total of 65/155 participants crossed over from chemotherapy to amivantamab after progression. The crossover-adjusted overall survival continued to demonstrate a favorable survival benefit for amivantamab-chemotherapy versus chemotherapy with HRs of 0.52-0.60, which is more pronounced than the planned interim intention-to-treat overall survival (HR of 0.67; 95% confidence interval 0.42-1.09). CONCLUSIONS: In PAPILLON, TTD and TTST were substantially longer for amivantamab-chemotherapy versus chemotherapy at primary analysis (cut-off on 3 May 2023). Crossover-adjusted analyses of the planned interim overall survival demonstrated a greater benefit for amivantamab-chemotherapy versus chemotherapy, further supporting amivantamab-chemotherapy as the first-line standard of care in EGFR exon 20 insertion-mutated non-small cell lung cancer. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04538664.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Fig. 3

Fig. 3 Crossover-adjusted overall survival (OS) for a inverse probability of censoring weighting (IPCW), b two-stage estimation (TSE), and c rank-preserving structural failure time (RPSFT). a P value calculated by assuming log (hazard ratio [HR]) is normally distributed. CI confidence interval, ITT intention-to-treat, mo months

A

overall survival (OS) - IPCW

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 2:extreme upward reversal曲线 3:extreme upward reversal
查看结果
B

overall survival (OS) - TSE

Fig. 3 · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal曲线 3:extreme upward reversal
查看结果
C

overall survival (OS) - RPSFT

Fig. 3 · Panel C

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:extreme jump曲线 3:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 a Time to treatment discontinuation (TTD) and b time to subsequent therapy (TTST). a TTD was defined as the time from randomization to discontinuation of all study treatments for any reason. b TTSD was defined as the time from the date of randomization to the start date of the first subsequent systemic anticancer therapy following study treatment discontinuation or death, whichever occurred first. CI confidence interval, HR hazard ratio, mo months, NE not estimable
非 KM Figure
Fig. 2Fig. 2 Most common first subsequent systemic therapy classes. a The “other” category included immuno-oncology (IO) alone and investigational agents. b In the amivantamab-chemotherapy and chemotherapy arms, 23% and 1% of participants received single-agent chemotherapy, respectively, and 7% and 1% of participants received doublet chemotherapy, respectively. EGFR epithelial growth factor receptor, TKI tyrosine kinase inhibitor, VEGFi vascular endothelial growth factor inhibitor
非 KM Figure